J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR ...

Rybrevant plus Lazcluze significantly extends overall survival in EGFR-mutated NSCLC compared to Tagrisso, with benefits continuing beyond the follow-up period. The combination therapy improves ...

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor ...

Among patients with EGFR-mutant non-small cell lung cancer, the COCOON trial regimen (Rybrevant [amivantamab] plus Lazcluze [lazertinib] plus enhanced dermatologic management) significantly reduced ...

Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer, after a recommendation from the EMA’s Human ...

The company is running a 1,000-patient study of Rybrevant in combination with lazertinib in patients with exon 19 or exon 21 mutations – a group that accounts for around 20% of the NSCLC population.

EXCLUSIVE: Indie filmmaker Kevin Cate has wrapped on the Georgia production of his debut feature, the holiday road trip comedy Unbearable Christmas. Principal cast for the film includes Julia ...